Exelixis

Exelixis’ exhibit at the American Society of Clinical Oncology (ASCO 2018) annual meeting featured the company’s new brand colors. Still the leader in the treatment of kidney cancer, the company’s Cabometyx continues to provide treatment superior to other therapies. The data is represented in the company’s graphics, “the power of three,” featuring three bulls and referring to the three endpoints supported by the data. The lattice motif is also a recurring feature in the Cabometyx campaign.